Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5874_Библиотеки_им_академика_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
31.08.2026
Размер:
27 Мб
Скачать
https://t.me/med1917
258
258
Luo, Bo, and Xinqiang Song. 2021. ‘A Comprehensive Overview of β- Carbolines and Its
β- Carbolines
Derivatives as Anticancer Agents’. European Journal of Medicinal Chemistry 224 (November): 113688. doi:10.1016/ j.ejmech.2021.113688
Mashkovskii, Mairla Deona, Natalia I. Andreeva, and Alex Ivanova Polezhaeva. 1980.
‘Monoamine Oxidase Inhibitors as Drugs’. Pharmaceutical Chemistry Journal 14 (2): 81– 86. doi:10.1007/ BF00765902
McKenna, Dennis J., G.H.N. Towers, and F. Abbott. 1984. ‘Monoamine Oxidase Inhibitors
in South American Hallucinogenic Plants: Tryptamine and β- Carboline Constituents of Ayahuasca’. Journal of Ethnopharmacology 10 (2): 195– 223. doi:10.1016/ 0378- 8741(84)90003- 5
Nakatsuka, Shin- ichi, Bai- nian Feng, Toshio Goto, and Kiyoshi Kihara. 1986. ‘Structures of
Flazin and YS, Highly Fluorescent Compounds Isolated from Japanese Soy Sauce’. Tetrahedron Letters 27 (29). Elsevier: 3399– 3402.
Onishi, Yoshiaki, Katsutaka Oishi, Yasuhiro Kawano, and Yoshimitsu Yamazaki. 2012. ‘The
Harmala Alkaloid Harmine Is a Modulator of Circadian Bmal1 Transcription’. Bioscience Reports 32 (1): 45– 52. doi:10.1042/ BSR20110002
Park, Tai Hwan, Oh Sang Kwon, Se Young Park, Eun Sook Han, and Chung Soo Lee. 2003.
‘N- Methylated β- Carbolines Protect PC12 Cells from Cytotoxic Effect of MPP+ by Attenuation of Mitochondrial Membrane Permeability Change’. Neuroscience Research 46 (3): 349– 358. doi:10.1016/ S0168- 0102(03)00097- X
Patel, K, M Gadewar, R Tripathi, SK Prasad, and Dinesh Kumar Patel. 2012. ‘A Review on
Medicinal Importance, Pharmacological Activity and Bioanalytical Aspects of Beta­Carboline Alkaloid “Harmine” ’. Asian Pacic Journal of Tropical Biomedicine 2 (8): 660– 664. doi:10.1016/ S2221- 1691(12)60116- 6
Peduto, Antonella, Rosanna Filosa, Paolo De Caprariis, Vincenzo De Feo, Shiyou Li, Ping
Wang, and Laura De Martino. 2012. ‘1- Methoxy- Canthin- 6- One and Related β- Carbolines: From Natural Compound to Synthesis and Biological Activities’. Studies in Natural Products Chemistry 38. Elsevier: 81– 104.
Peng, Jiangnan, Jin- Feng Hu, Abul B Kazi, Ze Li, Mitchell Avery, Olivier Peraud,
Russell T Hill, Scott G Franzblau, Fangqiu Zhang, and Raymond F. Schinazi. 2003. ‘Manadomanzamines A and B: A Novel Alkaloid Ring System with Potent Activity against Mycobacteria and HIV- 1’. Journal of the American Chemical Society 125 (44). ACS Publications: 13382– 13386.
Rao, Karumanchi V., Marwa S. Donia, Jiangnan Peng, Esther Garcia- Palomero, Diana Alonso,
Ana Martinez, Miguel Medina, et al. 2006. ‘Manzamine B and E and Ircinal A Related Alkaloids from an Indonesian Acanthostrongylophora Sponge and Their Activity against Infectious, Tropical Parasitic, and Alzheimer’s Diseases’. Journal of Natural Products 69 (7): 1034– 1040. doi:10.1021/ np0601399
Rao, Karumanchi V., Noer Kasanah, Subagus Wahyuono, Babu L. Tekwani, Raymond
F. Schinazi, and Mark T. Hamann. 2004. ‘Three New Manzamine Alkaloids from a Common Indonesian Sponge and Their Activity against Infectious and Tropical Parasitic Diseases’. Journal of Natural Products 67 (8): 1314– 1318. doi:10.1021/ np0400095
Réus, Gislaine Z., Roberto B. Stringari, Cinara L. Gonçalves, Giselli Scaini, Milena Carvalho-
Silva, Gabriela C. Jeremias, Isabela C. Jeremias, et al. 2012. ‘Administration of Harmine and Imipramine Alters Creatine Kinase and Mitochondrial Respiratory Chain Activities in the Rat Brain’. Depression Research and Treatment 2012: 1– 7. doi:10.1155/ 2012/
987397.
Sarter, Martin, Herbert H. Schneider, and David N. Stephens. 1988. ‘Treatment Strategies for
Senile Dementia: Antagonist β- Carbolines’. Trends in Neurosciences 11 (1): 13– 17. doi:10.1016/ 0166- 2236(88)90042- 2
https://t.me/med1917
259
β-Carbolines as Anti- HIV Agents
Selvaraj, Manikandan, Karthik Sadasivam, Muralidharan Jothimani, and Karthikeyan
259
Muthusamy. 2023. ‘A Comprehensive Computational Perspective in Drug Discovery for Alzheimer’s Disease’. Combinatorial Chemistry & High Throughput Screening 26 (12): 2113– 2123. doi:10.2174/ 1386207325666220606142910
Sliwoski, Gregory, Sandeepkumar Kothiwale, Jens Meiler, and Edward W. Lowe. 2014.
‘Computational Methods in Drug Discovery’. Pharmacological Reviews 66 (1): 334–
395. doi:10.1124/ pr.112.007336 Sneader, Walter. 2005. Drug Discovery: A History. John Wiley & Sons. Su, Bao- Ning, Leng Chee Chang, Eun Jung Park, Muriel Cuendet, Bernard D. Santarsiero,
Andrew D. Mesecar, Rajendra G. Mehta, Harry H. Fong, John M. Pezzuto, and A. Douglas Kinghorn. 2002. ‘Bioactive Constituents of the Seeds of Brucea Javanica’. Planta Medica 68 (8): 730– 733. doi:10.1055/ s- 2002- 33798
Suzuki, Hideharu, Makoto Adachi, Yuki Ebihara, Hiroshi Gyoutoku, Hinako Furuya, Yasuoki
Murakami, and Hiroaki Okuno. 2005. ‘A Total Synthesis of 1- Methoxycanthin- 6­One: An Efcient One- Pot Synthesis of the Canthin- 6- One Skeleton from β- Carboline- 1­Carbaldehyde’. Synthesis 2005 (01). © Georg Thieme Verlag Stuttgart· New York: 28– 32.
Tang, Jian- Guo, Yun- Hua Wang, Rui- Rui Wang, Ze- Jun Dong, Liu- Meng Yang, Yong-
Tang Zheng, and Ji- Kai Liu. 2008. ‘Synthesis of Analogues of Flazin, in Particular, Flazinamide, as Promising Anti- HIV Agents’. Chemistry & Biodiversity 5 (3): 447– 460. doi:10.1002/ cbdv.200890044
Vijayan, R.S.K., Jan Kihlberg, Jason B. Cross, and Vasanthanathan Poongavanam. 2022.
‘Enhancing Preclinical Drug Discovery with Articial Intelligence’. Drug Discovery Today 27 (4): 967– 984. doi:10.1016/ j.drudis.2021.11.023
Wang, Lingle, Yuqing Deng, Yujie Wu, Byungchan Kim, David N. LeBard, Dan Wandschneider,
Mike Beachy, Richard A. Friesner, and Robert Abel. 2017. ‘Accurate Modeling of Scaffold Hopping Transformations in Drug Discovery’. Journal of Chemical Theory and Computation 13 (1): 42– 54. doi:10.1021/ acs.jctc.6b00991
Xu, Zhihong, Fang- Rong Chang, Hui- Kang Wang, Yoshiki Kashiwada, Andrew T. McPhail,
Kenneth F. Bastow, Yoko Tachibana, Mark Cosentino, and Kuo- Hsiung Lee. 2000. ‘Anti­HIV Agents 45 and Antitumor Agents 205. Two New Sesquiterpenes, Leitneridanins A and B, and the Cytotoxic and Anti- HIV Principles from Leitneria f Loridana’. Journal of Natural Products 63 (12): 1712– 1715. doi:10.1021/ np000260u
Yonezawa, Takayuki, Shin- ichi Hasegawa, Midori Asai, Tadashi Ninomiya, Toshinori Sasaki,
Byung- Yoon Cha, Toshiaki Teruya, et al. 2011. ‘Harmine, a β- Carboline Alkaloid, Inhibits Osteoclast Differentiation and Bone Resorption in Vitro and in Vivo’. European Journal of Pharmacology 650 (2– 3): 511– 518. doi:10.1016/ j.ejphar.2010.10.048.
Yousaf, Muhammad, Nicholas L Hammond, Jiangnan Peng, Subagus Wahyuono, Kylie A
McIntosh, William N Charman, Alejandro M. S Mayer, and Mark T Hamann. 2004. ‘New Manzamine Alkaloids from an Indo- Pacic Sponge. Pharmacokinetics, Oral Availability, and the Signicant Activity of Several Manzamines against HIV- I, AIDS Opportunistic Infections, and Inammatory Diseases’. Journal of Medicinal Chemistry 47 (14). ACS Publications: 3512– 3517.
Zhang, Yun, and Andrew Pike. 2021. ‘Pyridones in Drug Discovery: Recent Advances’.
Bioorganic & Medicinal Chemistry Letters 38 (April): 127849. doi:10.1016/ j.bmcl.2021.127849
Zheng, Yajun, Colin M. Tice, and Suresh B. Singh. 2014. ‘The Use of Spirocyclic Scaffolds
in Drug Discovery’. Bioorganic & Medicinal Chemistry Letters 24 (16): 3673– 3682. doi:10.1016/ j.bmcl.2014.06.081
260
https://t.me/med1917
https://t.me/med1917
261
Index
Note: Page numbers in italic refers to gures/schemes.
A
abecarnil 58 activities of β- carbolines 52– 53
see also antibacterial properties of β- carbolines;
antifungal actions of β- carboline products; antimalarial activity of β- carbolines; antioxidant activity of β- carbolines
anti- HIV agents, biological activities exhibited
by β- carbolines 235– 236 anti- inammatory agents 226– 227 anticancer activity of β- carbolines 3, 31– 44 biological activities exhibited by β- carbolines
235– 236 pharmaceutical activities of β- carbolines 207
Akt kinase 110– 112 alangiobussine synthesis 65 alangiobussinine synthesis 65 Alzheimer’s disease 103, 104 anti- HIV agents 234– 255
biological activities exhibited by β- carbolines
235– 236 discovery and signicance of β- carbolines
236– 237 drug discovery overview 234– 236 drymaritin 240, 243 azin 238, 241, 243246 functionalization of the β- carboline scaffold
252– 254 future outlook 254– 255 harman 240, 241 harmine 236 HIV- 1 reverse transcriptase (RT) 243– 244, 247249 manzamine alkaloids 61, 241, 242 medicinally important β- carbolines based
compounds 236– 237 natural sources of β- carbolines 237– 238 neurotransmitter interaction 236– 237 scaffolds, importance of 234– 236 structural diversity of carbolines 235 synthesis of β- carbolines 237– 238, 245– 251
anti- inammatory agents, β- carboline as 226– 227 antibacterial properties of β- carbolines 53– 61
synthetic aspects of β- carbolines having
antibacterial property 67– 73
anticancer activity of β- carbolines 3
synthesis of β- carboline derivatives as
anticancer agents 34– 44 targeting multiple biological objectives 31– 34
antidepressant agents, β- carboline as 221– 225 antifungal actions of β- carboline products 88– 90 antifungal mediators, β- carboline products as 85– 88 antimalarial activity of β- carbolines 158– 175
malaria background 158– 160 synthesis of β- carbolines 160– 169 β- carboline derivatives 169– 174
antioxidant activity of β- carbolines 183– 194
dihydro β- carbolines 189 ethyl β- carboline- 3- carboxylate (β- CCE)
190– 193 future aspects 194 pharmacological active β- carbolines 180– 183 reactive oxygen species (ros) 191 recent advances 190– 193 synthetic β- carbolines 190 tetrahydro- β- carbolines 183– 186 β- carboline alkaloids 186– 188
applications of β- carbolines 73– 74 Aurora kinases 117– 118
B
B- Raf kinase 118
β- carboline alkaloids, antioxidant activity of
β- carbolines 186– 188
β- carboline- combretastatin carboxamide
conjugates 31– 34
β- CCE (ethyl β- carboline- 3- carboxylate),
antioxidant activity of β- carbolines 190– 193
biological activities exhibited by β- carbolines
235– 236
C
C- 7 position of β- carbolines 146 canthine synthesis 66– 67 CDC- like Kinase 1 (CLK1) 108– 110 CDKs (cyclin- dependent kinases) 23– 24, 96– 101 cell cycle as target, synthesis of β- carboline
derivatives as anticancer agents 29– 31
characteristics of β- carbolines 61– 62 chemical composition of several carboline kinds
204– 206
CLK1 (CDC- like Kinase 1) 108– 110 combilexins, DNA targeting agents 15– 19 compounds with unexplored mechanism of
action, synthesis of β- carboline derivatives as
anticancer agents 34– 44
261
https://t.me/med1917
262
262
cyclic aldimines, synthesis 67 cyclin- dependent kinases (CDKs) 23– 24, 96– 101 cyclometalated Ir (III) complexes 100 cyclometalated Ru(II) complexes 99
HDAC inhibitors, synthesis of β- carboline
derivatives as anticancer agents 26– 29
HIV see anti- HIV agents hybrid β- carbolines 130– 132 hyrtioerectines 61
Index
D
depression, β- carboline as antidepressant agents
221– 225 derivatives of carboline alkaloids 61, 62 diabetes, kinases inhibitors 103– 104 dihydro β- carbolines 189 discovery and signicance of β- carbolines
236– 237 DNA targeting agents
combilexins 15– 19 DNA groove- binding agents 9– 14 intercalating agents 3– 8 scission 19– 21 synthesis of β- carboline derivatives 3– 21 topoisomerase inhibitors 14– 15 drug discovery overview 234– 236 drymaritin 240, 243
dual- specicity Tyrosine Phosphorylation-
regulated Kinases (DYRKs) 101– 104
E
epigallocatechin gallate (EGCG) 104 ethyl β- carboline- 3- carboxylate (β- CCE),
antioxidant activity of β- carbolines 190– 193 eudistomins- Y and its analogues 53, 54
F
fascaplysin 98– 99 azin 238, 241, 243246 functionalization of β- carbolines 134– 147,
252– 254 future aspects, antioxidant activity of
β- carbolines 194 future outlook, anti- HIV agents 254– 255 future perspectives, synthesis of β- carboline
derivatives as anticancer agents 44
G
Glycogen Synthase Kinase (GSK) 115– 116
H
harmaline 57, 82– 83, 101 harman 240, 241 harmane 55– 56, 60 harmine 82– 83, 96, 102– 103, 236 haspase kinase inhibitors 21– 23 haspin kinase inhibitors 21– 23, 116– 117
I
IKK (IκB kinase) 107– 108 intercalating agents, DNA targeting agents 3– 8 IκB kinase (IKK) 107– 108
K
kinases as target
cyclin- dependent kinases (CDKs) 23– 24 haspin kinase inhibitors 21– 23 synthesis of β- carboline derivatives as
anticancer agents 21– 24
kinases inhibitors 94– 120
Akt kinase 110– 112 Alzheimer’s disease 103, 104 Aurora kinases 117– 118 B- Raf kinase 118 CDC- like Kinase 1 (CLK1) 108– 110 cyclin- dependent kinases (CDKs) 23– 24, 96– 101 cyclometalated Ir (III) complexes 100 cyclometalated Ru(II) complexes 99 diabetes 103– 104 dual- specicity Tyrosine Phosphorylation-
regulated Kinases (DYRKs) 101– 104 epigallocatechin gallate (EGCG) 104 fascaplysin 98– 99 Glycogen Synthase Kinase (GSK) 115– 116 harmaline 101 harmine 96, 102– 103 haspin kinase 116– 117 IκB kinase (IKK) 107– 108 manzamine A 100 mezamine A 100 Mitogen- activated Protein Kinase- activated
Protein Kinase 2 (MAPKAPK2) 105– 107 platelet- derived growth factor (PDGF) 118– 119 Polo- like Kinases (PLKs) 113– 115 Protein Kinase B (PKB or Akt) 110– 112 protein tyrosine kinase 6 (PTK6) 118 pyrrolo[2,3- a] carbazole analogs 98 Ru (II)- containing arene entities 99– 100 SK1/ sphingosine- 1- phosphate pathway 119 Suzuki- Miyaura reaction 99 tau phosphorylation 103 tryptamine and tetrahydro- β- C biphenyl
derivatives 99
kinesin (Eg5) inhibitors, synthesis of β- carboline
derivatives as anticancer agents 26
komavine synthesis 65– 66
https://t.me/med1917
263
Index
M
malaria see antimalarial activity of β- carbolines manzamine A 100 manzamine alkaloids 61, 241, 242 MAPKAPK2 (Mitogen- activated Protein Kinase-
activated Protein Kinase 2) 105– 107
marine alkaloid oriented β- carboline
synthesis 84– 85
medicinally important β- carbolines based
compounds 236– 237 mezamine A 100 Mitogen- activated Protein Kinase- activated
Protein Kinase 2 (MAPKAPK2) 105– 107
N
N(2)- substituted β- carbolines 132– 134 natural products having a simple β- carboline
skeleton 63- 67 natural sources of β- carbolines 237– 238 naturally occurring β- carboline alkaloids 95 neamine- carboline conjugates 55 neurotransmitter interaction 236– 237 norharman synthesis 63
O
occurrence of β- carbolines 62- 63
P
PDGF (platelet- derived growth factor) 118– 119 pharmaceutical activities of β- carbolines 207 pharmacological active β- carbolines 180– 183 pharmacologically interesting β- carbolines 55, 56 PKB or Akt (Protein Kinase B) 110– 112 plakortamine 60 platelet- derived growth factor (PDGF) 118– 119 Polo- like Kinases (PLKs) 113– 115 Protein Kinase B (PKB or Akt) 110– 112 protein tyrosine kinase 6 (PTK6) 118 pyrrolo[2,3- a] carbazole analogs 98
R
reactive oxygen species (ROS), antioxidant
activity of β- carbolines 191 Ru (II)- containing arene entities 99– 100
SK1/ sphingosine- 1- phosphate pathway 119 sources of β- carbolines 53– 54 stolonine synthesis 64 structural diversity of carbolines 1– 2, 55– 61, 95,
160, 161, 180, 206– 208, 235 sulfanyl derivatives of β- carbolines 135– 139 sulfone derivatives of β- carbolines 142– 145 sulfur- containing β- carbolines 126– 151
C- 3 functionalization of β- carbolines 134– 145 C- 6 sulfur- containing β- carbolines 145 C- 7 position of β- carbolines 146 drug design 129– 147 hybrid β- carbolines 130– 132 N(2)- substituted β- carbolines 132– 134 S- functionalization at the N(9)- position of
β- carbolines 146– 147
sulfanyl derivatives of β- carbolines 135– 139 sulfone derivatives of β- carbolines 142– 145 synthesis 129– 147 thiocarbamide and thione derivatives of
β- carbolines 139– 142
transition metal complexes involving
β- carbolines as N- ligands 147– 151 Suzuki- Miyaura reaction 99 synthesis of tetrahydro- β- carbolines 163,
218– 221 synthesis of β- carboline derivatives 206– 221 synthesis of β- carboline derivatives as anticancer
agents 3– 44
cell cycle as target 29– 31 compounds with unexplored mechanism of
action 34– 44
DNA targeting agents 3– 21 future perspectives 44 HDAC inhibitors 26– 29 kinases as target 21– 24 kinesin (Eg5) inhibitors 26 targeting multiple biological objectives
31– 34
tubulin/ microtubule as a target 24– 25
synthesis of β- carbolines 64, 65, 238
anti- HIV agents 237– 238, 245– 251 antimalarial activity of β- carbolines 160– 169 marine alkaloid focus 84– 85
synthetic β- carbolines
antioxidant activity 190 having antibacterial property 67– 73
263
S
S- functionalization at the N(9)- position of
β- carbolines 146– 147 SARs analysis of β- carbolines 180 scaffolds, importance of 234– 236 scission, DNA targeting agents 19– 21 shishijimicin A synthesis 66
T
tau phosphorylation 103 tetrahydro- β- carbolines 83– 84
antioxidant activity of β- carbolines 183– 186 stereoisomers 170 synthesis 163, 218– 221
https://t.me/med1917
264
264
tryptamine and tetrahydro- β- C biphenyl
derivatives 99 tetrahydroharmane synthesis 64– 65 thiocarbamide and thione derivatives of
β- carbolines 139– 142 topoisomerase inhibitors, DNA targeting
agents 14– 15 transition metal complexes involving β- carbolines
as N- ligands 147– 151
tryptamine and tetrahydro- β- C biphenyl
derivatives 99
tubulin/ microtubule as a target, synthesis of
β- carboline derivatives as anticancer agents 24– 25
Y
yohimbine 58– 59
Index